How a pool of 'tired' cancer-fighting immune cells affects anti-PD-1 therapy
Role of progenitor exhausted CD8 T cells and the progenitor niche in anti-PD1 efficacy
This research looks at whether a reservoir of 'exhausted' CD8 immune cells helps or limits anti-PD-1 cancer treatment for people receiving these immunotherapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11171570 on NIH RePORTER |
What this research studies
From my perspective as a patient, the team wants to understand why many people show immune reawakening after anti-PD-1 drugs but still do not get cured. Researchers will study a stem-like pool of 'progenitor' exhausted CD8 T cells that supply the tumor-fighting cells and how anti-PD-1 speeds their differentiation. They will use tumor and blood samples alongside laboratory models to map the cells and the local 'niche' signals that support them. The work aims to identify ways to protect or replenish that progenitor pool so immunotherapy leads to more durable responses.
Who could benefit from this research
Good fit: Ideal candidates are people with cancers treated with anti-PD-1 drugs who can provide tumor or blood samples, for example patients starting or on PD-1 therapy and willing to undergo biopsies or blood draws.
Not a fit: Patients whose cancers are not treated with PD-1 blockade or who cannot provide tumor or blood samples are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost the durability of anti-PD-1 treatments so more patients achieve lasting tumor control.
How similar studies have performed: Previous work has shown that anti-PD-1 reawakens a stem-like subset of exhausted CD8 T cells and can produce rapid tumor control in some patients, but turning that effect into consistent cures remains unproven.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Huang, Alexander — University of Pennsylvania
- Study coordinator: Huang, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.